Kymera Therapeutics, Inc. Common Stock (KYMR) Stock Price
KYMRStock
$104.78+73.30%52W
Market Cap$8.71B
P/E—
PEG Ratio—
Div yield—
Beta2.05
KYMR Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)6.69%
Price vs S&P 500 (4W)-9.63%
VGM Score54.70
KYMR Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.74 | -$0.62 | +15.98%(+$0.12) | |
| Q1 2026 | -$0.86 | -$0.71 | +17.05%(+$0.15) | |
| Q4 2025 | -$0.77 | -$0.98 | -27.09%(-$0.21) | |
| Q3 2025 | -$0.78 | -$0.94 | -20.26%(-$0.16) | |
| Q2 2025 | -$0.80 | -$0.95 | -19.13%(-$0.15) |
KYMR Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.30
4.28
4.20
4.20
Industry Peers — Biological Products(186)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|---|---|---|
KYMRKymera Therapeutics, Inc. Common Stock | F | B | B | 83.0x | 134.8% | — | — | $104.78 |
| AMGNAmgen Inc | D | C | A | 6.1x | 9.1% | 74.3% | 2.9% | $432.49 |
| GILDGilead Sciences Inc | C | B | A | 6.4x | 5.5% | 79.6% | 133.6% | $156.19 |
| MRNAModerna, Inc. Common Stock | F | C | A | 39.1x | -27.6% | 36.4% | — | $218.01 |
| ARGXargenx SE American Depositary Shares | D | A | B | 6.6x | 165.2% | 89.8% | — | $819.14 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | B | 3296.2x | — | — | — | $177.96 |
| BIIBBiogen Inc. Common Stock | C | D | A | 3.4x | 0.3% | 74.0% | -18.8% | $232.65 |
| BNTXBioNTech SE American Depositary Share | C | C | C | 7.6x | -11.8% | 79.2% | — | $87.71 |
| EXELExelixis Inc | C | B | A | 6.3x | 9.2% | 96.5% | 31.1% | $62.23 |
| HALOHalozyme Therapeutics, Inc. | D | B | A | 8.3x | 41.1% | 82.4% | 22.9% | $121.84 |
| NBIXNeurocrine Biosciences Inc | C | B | B | 4.1x | 34.4% | 98.0% | 2.3% | $135.71 |
About Kymera Therapeutics, Inc. Common Stock
Kymera Therapeutics is a clinical-stage biopharmaceutical company developing novel small molecule medicines targeting STAT6, TYK2, and IRAK4—proteins with known disease-causing biology that remain undrugged or inadequately treated with existing therapies. The company uses proprietary technologies to overcome limitations that have previously prevented effective drug development against these targets. Its disease-agnostic approach aims to generate a differentiated pipeline addressing multiple therapeutic areas with these validated biological targets.